<SEC-DOCUMENT>0001144204-16-098123.txt : 20160502
<SEC-HEADER>0001144204-16-098123.hdr.sgml : 20160502
<ACCEPTANCE-DATETIME>20160502080014
ACCESSION NUMBER:		0001144204-16-098123
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20160502
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160502
DATE AS OF CHANGE:		20160502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		161609758

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v438425_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>May 2, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tlogo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center"><FONT STYLE="font-size: 10pt">99-0370688</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer</FONT><BR>
<FONT STYLE="font-size: 10pt">Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)(Zip
Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 7.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosures</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 2, 2016, Lipocine Inc. issued a press release announcing
the presentation of TLANDO&trade; (&ldquo;LPCN 1021&rdquo;) clinical data at the 2016 American Urological Association Meeting in
San Diego, CA. The press release is filed as Exhibit 99.1 and is incorporated herein by reference. Additionally, the Company submitted
two abstracts containing TLANDO clinical data at the 2016 American Urological Association Meeting in San Diego, CA and one abstract
at the American Association for Clinical Endocrinologists Annual Meeting in Orlando, FL. The Company&rsquo;s abstracts are filed
as Exhibit 99.2, Exhibit 99.3 and Exhibit 99.4 and are incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left">Item 9.01</TD><TD STYLE="text-align: justify">Financial Statements and Exhibits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed with this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 86%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press Release Announcing the Presentation of TLANDO Clinical Data at the 2016 American Urological Association Meeting</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Abstract Concerning Long-term Safety and Tolerability of Oral Testosterone (LPCN 1021) in Hypogonadal Men: Results from the 52-Week Phase 3 Study</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstract Concerning Hypogonadal Men with Sexual Function Disorder Benefit from LPCN 1021 (Oral Testosterone) &ndash; SOAR (Study of Androgen Replacement) Trial</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstract Concerning Hypogonadal Men with Diabetes Benefit from LPCN 1021 (Oral Testosterone) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">LIPOCINE INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">May 2, 2016</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v438425_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tlogo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>For Immediate Release</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE ANNOUNCES THE PRESENTATION OF
CLINICAL DATA FOR ORAL TESTOSTERONE REPLACEMENT THERAPY PRODUCT CANDIDATE TLANDO&trade; (&ldquo;LPCN 1021&rdquo;) AT THE 2016 AMERICAN
UROLOGICAL ASSOCIATION ANNUAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SALT LAKE CITY (May 2, 2016)<I> &ndash;</I></B><I> </I><U>Lipocine
Inc.</U> (NASDAQ: LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO&trade;
(&ldquo;LPCN 1021&rdquo;), will be presented in poster and podium presentations at the 2016 American Urological Association Annual
Meeting being held May 6-10 in San Diego, CA. TLANDO is an oral testosterone replacement therapy (&quot;TRT&quot;) product candidate
being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known
as hypogonadism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 85%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Hypogonadal Men with Sexual Function Disorder Benefit from LPCN 1021 (Oral Testosterone) &ndash; SOAR (Study of Androgen Replacement) Trial</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Abstract No.:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">MP76-10</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date/Time:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Monday, May 9, 2016, 3:30 &ndash; 5:30 p.m. PT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Location:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">San Diego Convention Center, Room 24</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Presenter:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Culley C. Carson III, MD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Rhodes Distinguished Professor, University of North Carolina Department of Urology</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President, American Society for Men's Health</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Congress President, International Society of Men&rsquo;s Health</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Long-term Safety and Tolerability of Oral Testosterone (LPCN 1021) in Hypogonadal Men:&nbsp;&nbsp;Results from the 52-Week Phase 3 Study</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Abstract No.:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">PD50-06</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date/Time:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tuesday, May 10, 2016, 10:30 a.m. &ndash; 12:30 p.m. PT</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Location:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">San Diego Convention Center, Room 23AB</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Presenter:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Mohit Khera, MD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Associate Professor, Urology, Baylor College of Medicine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director, Laboratory for Andrology Research</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Medical Director, Houston Hospital for Specialized Surgery</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About TLANDO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TLANDO is a novel twice-a-day oral testosterone replacement
therapy product candidate that is designed to help restore normal testosterone levels in hypogonadal men. The safety and efficacy
of TLANDO is currently under FDA review. Lipocine expects TLANDO will help fulfill an unmet need in the treatment of hypogonadism.
The current testosterone market primarily uses short-acting injectable products as well as topical products that carry an FDA &quot;black
box&quot; warning related to inadvertent transfer of testosterone to others. According to the IMS Health database, an average of
half a million prescriptions a month have been dispensed in 2016 for TRT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Lipocine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. TLANDO,
an oral testosterone replacement therapy product candidate, demonstrated positive efficacy and safety results in Phase 3 testing
and has a New Drug Application under review with the FDA. LPCN 1111, a next-generation oral testosterone replacement therapy product
with once-daily dosing, is currently in Phase 2 testing. LPCN 1107, which has the potential to become the first oral hydroxyprogesterone
caproate product indicated for the prevention of recurrent preterm birth, is currently in Phase 1 testing and has been granted
orphan drug designation by the FDA. For more information, please visit <U>www.lipocine.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This release contains &ldquo;forward looking statements&rdquo;
that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements
that are not historical facts relating to Lipocine&rsquo;s common stock, the FDA review process relating to our product candidates
and the possible outcome of such process, clinical trials, the potential uses and benefits of our product candidates, product development
and commercialization efforts and the projected timing and outcome of regulatory filings and actions. Investors are cautioned that
all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks related to our products,
expected product benefits, clinical and regulatory expectations and plans, regulatory developments and requirements, risks related
to the FDA&rsquo;s review of our NDA for TLANDO, the receipt of regulatory approvals, the results of clinical trials, patient acceptance
of Lipocine&rsquo;s products, the manufacturing and commercialization of Lipocine&rsquo;s products, the risks related to market
conditions for Lipocine&rsquo;s common stock and other risks detailed in Lipocine&rsquo;s filings with the SEC, including, without
limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov.
Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as
required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTACT: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President &amp; Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>mb@lipocine.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Woolford</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (443) 213-0500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>john.woolford@westwicke.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Heather Anderson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (919) 827-5539</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>handerson@6degreespr.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>v438425_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUA Abstract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Word Count: 2280 characters (not including spaces, but including
title) allowed; current draft has 2268 characters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Long-term Safety and Tolerability of Oral Testosterone (LPCN
1021) in Hypogonadal Men: Results from the 52-Week Phase 3 Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mohit Khera, MD<SUP>1</SUP>, Christina Wang, MD<SUP>2</SUP>,
Jed C. Kaminetsky, MD<SUP>3</SUP>,<I> </I>Martin M. Miner, MD<SUP>4</SUP>,<I> </I>Adrian S Dobs, MD, MHS<SUP>5</SUP>,<SUP> </SUP>Nachiappan
Chidambaram<SUP>6</SUP>, Anthony DelConte, MD<SUP>6,7</SUP>, Satish Nachaegari<SUP>6</SUP>, Mahesh Patel<SUP>6</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I><SUP>1</SUP>Baylor
College of Medicine, Houston, TX, <SUP>2</SUP>Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance,
CA, <SUP>3</SUP>University Urology Associates, New York, NY, <SUP>4</SUP>Brown University and the Miriam Hospital, Providence,
RI, <SUP>5</SUP>Johns Hopkins University School of Medicine, Baltimore, MD,</I></FONT>&nbsp;<FONT STYLE="background-color: white"><I><SUP>6</SUP>Lipocine,
Inc. Salt Lake City, UT, <SUP>7</SUP>Saint Joseph&rsquo;s University, Philadelphia, PA</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Introduction:</B> <FONT STYLE="font-family: Times New Roman, Times, Serif">LPCN
1021 is a novel oral testosterone undecanoate (TU) formulation, absorbed primarily via lymphatics bypassing the liver. </FONT>LPCN
1021 has been shown to be safe and efficacious after 13 weeks in a randomized, active-controlled Phase 3 study.<SUP>1</SUP> We
report long-term safety and tolerability of LPCN 1021 in hypogonadal subjects who continued receiving treatment for up to 52 weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Methods:</B> Hypogonadal patients (serum T levels &lt; 300
ng/dL) were randomized in a 2:1 ratio to LPCN&nbsp;1021 or T gel 1.62% (active control) and titrated to a successful dose of the
assigned treatment. Following a 13-week efficacy phase, subjects continued receiving their assigned study drug for up to 52 weeks.
Subjects returned to the clinic at Weeks 26, 39, and 52 for safety assessments and to provide a 3 to 6 hour post dose blood sample.
Safety assessments included an evaluation of adverse events (AEs), clinical laboratory tests, and physical examinations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results:</B> 210 subjects were randomized to LPCN 1021 and
105 to active control. Eugonadal T levels were restored with LPCN 1021 (Week 13 mean [SD] Cavg of 446 [171] ng/dL) and were reliably
maintained throughout 52 weeks. AEs occurred in 67% of LPCN 1021 subjects and 65% of T gel 1.62% subjects. No hepatic, cardiac,
or drug-related serious AEs occurred. The most common drug-related AEs (adverse drug reactions, ADRs) for LPCN 1021 and T gel 1.62%
were acne (2.9% vs 2.9%, respectively), headache (0.5% vs 3.8%, respectively), weight increase (2.4% vs 0%, respectively), hematocrit
increase (1.9% vs 0%, respectively), liver enzyme level increase (1.4% vs 0%, respectively), fatigue (0.5% vs 1.9%, respectively),
and hypertension (0.5% vs 1.9%, respectively). All ADRs were mild or moderate in severity. Subjects receiving LPCN 1021 reported
few androgenic ADRs with no reports of sleep apnea or oily skin and 1% or fewer subjects reporting peripheral edema and polycythemia.
Most lipid parameters (cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52. Other androgenic parameters
including hematocrit, hemoglobin, platelet, prothrombin, and PSA showed no significant differences in change from baseline to end
of study between treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conclusions:</B> LPCN 1021 was well tolerated and had a favorable
safety profile in the long-term management of hypogonadal subjects. Notably, no hepatic safety concerns were identified and gastrointestinal
AEs with oral LPCN 1021 were generally comparable to active control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>Wang C, et al. Endo Rev. 2015;36(2) Suppl. Abstract
OR34-5.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Keywords:</B> Testosterone, clinical trial, hormonal therapy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>v438425_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AUA abstract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Word Count: 2280 characters (not including spaces, but including
title) allowed; current draft has 2261 characters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Hypogonadal Men with Sexual Function Disorder Benefit from
LPCN 1021 (Oral Testosterone) &ndash; SOAR (Study of Androgen Replacement) Trial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Culley C. Carson, MD<SUP>1</SUP>, Mohit Khera, MD<SUP>2</SUP>,
Adrian S Dobs, MD, MHS<SUP>3</SUP>,<SUP> </SUP>Christina Wang, MD<SUP>4</SUP>, Jed C. Kaminetsky, MD<SUP>5</SUP>, Irwin Goldstein,
MD<SUP>6</SUP>, Anthony DelConte, MD<SUP>7,8</SUP>, Nachiappan Chidambaram<SUP>8</SUP>, Satish Nachaegari<SUP>8</SUP>, Mahesh Patel<SUP>8</SUP>,
Martin M. Miner, MD<SUP>9</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I><SUP>1</SUP>Department
of Urology, University of North Carolina, Chapel Hill, NC,<SUP>2</SUP>Baylor College of Medicine, Houston, TX, <SUP>3</SUP>Johns
Hopkins University School of Medicine, Baltimore, MD,<SUP>4</SUP>Harbor-UCLA Medical Center and Los Angeles Biomedical Research
Institute, Torrance, CA, <SUP>5</SUP>University Urology Associates, New York, NY,</I></FONT>&nbsp;<SUP>6</SUP><FONT STYLE="background-color: white"><I>Alvarado
Hospital, San Diego, CA, <SUP>7</SUP>Saint Joseph&rsquo;s University, Philadelphia, PA, <SUP>8</SUP>Lipocine, Inc. Salt Lake City,
UT,<SUP> 9</SUP>Brown University and the Miriam Hospital, Providence, RI</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Introduction:</B>&nbsp; Sexual dysfunction (SD) has been
associated with hypogonadism.<SUP>1</SUP> Testosterone (T) therapy is indicated for treating hypogonadism and related symptoms.
However, topical or parenteral T formulations are associated with inadvertent T transference, poor compliance, and superphysiologic
T levels in some patients. There is a need for T formulations that improve patient compliance, mitigate transference, and achieve
more consistent serum T levels. LPCN 1021 is a novel oral T undecanoate formulation assessed in a Phase 3 (SOAR) trial that may
avoid some of the undesirable attributes of non-oral T formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Methods:</B>&nbsp; SOAR is a randomized, active&ndash;controlled,
2-arm, 12-month, open-label, multicenter, dose-titration trial that included 314 hypogonadal (T&lt;300ng/dl on 2 separate days)
men between 18 and 80 years old. &nbsp;Participants were randomized to either LPCN 1021 (n=210) or T gel&nbsp;1.62% (n=104).&nbsp;
Of the 314 hypogonadal men, 88 (28%) had SD at baseline. Subjects with baseline SD had poorer quality erections (p=0.011) and more
difficulty maintaining erections (p=0.017) than hypogonadal subjects without SD. The LPCN 1021 dose could be titrated up (e.g.
if T C<SUB>ave</SUB>,<SUB> 24h</SUB> &lt;300 mg/dL) or down (e.g. if T C<SUB>max</SUB> was &gt;1500 mg/dL) at Weeks 4 and 8 based
on 24 h PK, if required.&nbsp;T gel 1.62% was titrated based on manufacturer&rsquo;s instruction. Sexual function and mood changes
were assessed by the Psychosexual Daily Questionnaire (PDQ) for 7 days preceding visits. Quality of life (QoL) was assessed by
the SF-36 questionnaire at Weeks 1 and 52 (end of study).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Results:</B><FONT STYLE="font-family: Times New Roman, Times, Serif">
&nbsp;</FONT>Hypogonadal subjects with SD were significantly older (p=0.001), and had lower serum estradiol levels (p=0.043); baseline
T levels were not significantly different. Sexual desire and activity, which were similar in both groups at baseline, improved
to a similar extent in each group. In men with and without SD, LPCN 1021 significantly improved penile rigidity (p&lt;0.001 and
p=0.028, respectively) and ability to maintain an erection (p&lt;0.001 and p=0.007, respectively). Non-significant differences
were observed for the same with T gel 1.62%. In addition, LPCN 1021 significantly improved depressed mood (p=0.002), mental health
(p=0.023) and mental component summary (p=0.008) in hypogonadal subjects with SD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Conclusions:</B>
Twice daily administration of oral LPCN 1021 over 52 weeks improved several parameters of sexual function in hypogonadal men with
SD prior to treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><SUP>1</SUP>Cunningham
GR, et al. J Clin Endocrinol Metab. 2015 Mar;100(3):1146-55.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>v438425_ex99-4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT 99.4</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Am Assoc Clin Endo: Wang C, Kaminetsky
JC, Miner MM, et al. 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>American Association for Clinical Endocrinologists Annual
Meeting, May 25-29, 2016 &ndash; Orlando, FL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>HYPOGONADAL MEN WITH DIABETES BENEFIT FROM LPCN 1021 (ORAL
TESTOSTERONE) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christina Wang, MD<SUP>1</SUP>, Jed C. Kaminetsky, MD<SUP>2</SUP>,
Martin M. Miner, MD<SUP>3</SUP>, Adrian S Dobs, MD, MHS<SUP>4</SUP>, Anthony DelConte, MD<SUP>5,6</SUP> Nachiappan Chidambaram<SUP>6</SUP>,
Satish Nachaegari<SUP>6</SUP>, Mahesh Patel<SUP>6</SUP>, Mohit Khera, MD<SUP>7</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><I><SUP>1</SUP>Harbor-UCLA
Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, <SUP>2</SUP>University Urology Associates, New York,
NY,<SUP> 3</SUP>Brown University and the Miriam Hospital, Providence, RI, <SUP>4</SUP>Johns Hopkins University School of Medicine,
Baltimore, MD,<SUP> 5</SUP>Saint Joseph&rsquo;s University, Philadelphia, PA, <SUP>6</SUP>Lipocine, Inc. Salt Lake City, UT,<SUP>
7</SUP>Baylor College of Medicine, Houston, TX</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Objective</B>:&nbsp;Hypogonadism is more prevalent in men
with type 2 diabetes mellitus (DM). Testosterone (T) therapy is indicated for treating hypogonadism and related symptoms. LPCN
1021 is a novel oral T undecanoate formulation that may avoid some undesirable attributes of non-oral T formulations, such as transference
or skin irritation. We sought to determine the effect of LPCN 1021 use in hypogonadal men with DM vs those without DM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Methods</B>:&nbsp;This was a randomized, active&ndash;controlled,
2-arm, 12-month, open-label, multicenter, dose-titration trial in hypogonadal (T&lt;300ng/dL on 2 separate days) men between 18
and 80 years old. Subjects were randomized to either LPCN 1021 (n=210) or Androgel&nbsp;1.62% (n=104).&nbsp;Of 314 hypogonadal
men, 82 (26%) reported medical history of DM. The LPCN 1021 dose could be adjusted based on T Cmax and T Cavg levels at weeks 4
and 8, if required.&nbsp;Sexual function and mood changes were assessed by the Psychosexual Daily Questionnaire (PDQ) for 7 days
preceding visits. Quality of life (QoL) was assessed by the SF-36 questionnaire at Weeks 1 and 52 (end of study, EOS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Results</B>:
Hypogonadal (HG) men with DM were significantly (p&lt;0.05) older (57 vs 52 years), with higher baseline HbA1c (7.5% vs 5.6%),
lower QoL scores (physical functioning, role physical, general health and physical component summary) and lower PDQ scores (sexual
desire, sexual pleasure with partner, and erectile function) than HG men without DM. Significant (p&lt;0.05) reduction in sexual
hormone binding globulin (22.8 vs 29.8 nmol/L) and HDL (1.1 vs 1.2 mmol/L) occurred post LPCN 1021 therapy (EOS) for HG men with
DM vs baseline; significant (p&lt;0.05) improvement in free T level (10.9 vs 5.8 ng/dL) and PDQ parameters (sexual desire and activity,
sexual pleasure, erectile function, positive and negative mood) were observed for HG men with DM at EOS vs baseline. Mean T (430
vs 483 ng/dL), DHT (105 vs 117 ng/dL) and estradiol Cavg (26 vs 29 pg/mL) were comparable (p&gt;0.05) between HG men with and without
DM at Week 13 (efficacy visit) post LPCN 1021 therapy, respectively. Parameters that showed significant improvements post LPCN
1021 in HG men with DM also showed significant improvements in men without DM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Discussion</B>:
HG men with DM had significantly lower baseline scores for some QoL and sexual function scores vs HG men without DM. HG men with
and without DM improved significantly in sexual domains post LPCN 1021, similar to men without DM. T, DHT and E2 levels were comparable
post LPCN 1021 between HG men with and without DM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conclusion</B>: LPCN 1021 is an effective treatment in HG
men with or without DM for restoring serum T levels to the physiological range and relieving some HG symptoms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ .@#V P$1  (1 0,1 ?_$ -8   (" @(# 0
M       *" D&!P,% 00+ @$! 0$  @,!              $"!08#! <($
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MO3VEHNU]N%[L"S1:#.5=Q!09)ET9]8L)70"B<25^602.K /#^[0.0 (;M4!
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M4Q_<'44.J1>@MO6D-S;-E,^TKTJ#R,@W:UMGGG;M%P\<H4IXCXD98TIAZNQ
MI_VA%@]4!,RQ0X$36.</((#PG2GI)ZK6EI&B(T1&B)43VJAK5S81VMO')6GY
MX)Y-N+6-,82>>_FNO4@5GRIAP[06GQFA'=IP'E W)Q_P:A67*B#-*LM*;QNF
MNWS(+HL(.#=BK=8KGM56YJT>S'31%<KW]S%(X:%1*\ @B0J' 1\NHHOI+I F
M5-,J($!$I" D"8%!,$P* $!,"^Y @%X<.'DX:TMK]Z(C1$:(C1$B_P!#'ZYO
M<!_)W<5](4)K(61>C8[_ 'C[*/ZWMS_^PE=47H+TZ-G3!^-=Q^)[KA;+E;9V
MFA7R&<0\U&.TR"=+M YF<I'+F*8S&8B7A2.&C@GNT5TRF#[ @-6DDWCJWYY]
MGDW\O\=7QQ/7K:/EQV@X7>IIJ$C[I1#NTVK&_P ,T QF++)>/04%"1:E$IET
M@,3B*2R*FLW+-Q3QV/[]3LITFK9&Q]8(VU4FZ0C"Q5BQ1*Y7,?+1$D@5=JZ0
M4+Y0$2FY3D, '34*8AP*8H@&EI(^>SH_6FY__5)GGZ:J+K(61>K0\QV;VE%'
M+V54<0U/#B^)DLCW=+%R[]IB S];':=EDBTM5Z9_.)OQ=J5P&PJ"N4JO.(\X
M ;B&K:K:M<?G5[4K_P##L(_^3PK_ !_I:EJVE@ZR^TCKYEQ8CFNJ8>;X?5O=
M;3R>O&M,0ED$:.:11"Q*,C1LXK( Y)'\XD[$IE./^2 CI:EJ9EU54:(D2/9E
M?K"LX_U;KS]+.--07K(O3V^JM(T1(K;^/[QEBG]=>V'^!ZQJ=*SZ2S7KY?6P
M[1OWKA7Z6(W0WH;T[>A]P1_U2?\ H!JK2\]DD*@+"FGVP$[,%>0O: 3B(\@*
M<.;DXF$>''AY=$7)HB4*]HZV57^"NV/>HUAAM(&<4]&N5S+*T.B<SNJ/:Q(@
MZQ_D54$#=L>.!5;XN?J '!$J;83<"&.8L.U9(Z5=UTO^I+B[J#8-@YEC,QL1
MG.IQ$=&YAQLX<H(3,?/-VJ*+NSPS$014D*C/N %9NX1(*:!CB@IRG*'-0J#%
M6=Z*HT18I>;U3<9U&P7W(-FAJ=3*K&N9BPV6P/T(V(B8YH05%G+MVX,0A0X!
MP(4.)U#B!" 8Q@ 2)$[=-DV[]>GJ7X^Q'@V-DRX QF=:O0\^Z;JD:Q>,RS;)
MWDC+L\BJ5N,:I:BM44&+0Y@6430:I ';&,76;UDVE6'^T-].R1/A;!^Y3!$"
M_6:;8*3%XJNT5#D54EF&+8A.-;U"V)>;?NA<]1>LRIN%"E R2"W:?]D>%(0C
MI5CO1NZI=!WQ83K..+K9(R(W28WK[6(NU5>N$&CJ]QD0@FU:Y$J:)@2)(LY%
MJ0AGZ"/,HR= ?F#LA(<0*H*NPU54:(L:N-RJF/:M.W:\V*'J50K$:YF+#9+
M_;Q</#QC-,57+Q^^=J)H((ID#_"/$PB   B(!HBJ4VQ]:W;GO#W)!MQV_8TS
M=>'1',NJ\R22M1$?C^,J\/SD6N<F[>SB4JP@GJX$3:E5;%=.3JD B0^7A(J
MQ2]_0Q^N;W ?R=W%?2%":@4%Z-CO]X^RC^M[<_\ ["5U1>@O3T&JM*$._P"V
M,XNW^;?K%AG(+="/G$TUIC&M\3:E6EZ!=D$#EC9ED<#)K+1RY^"+]IS@F[:F
M,4P<P$,4H;4K_P!*7>WE'I;;FK1TVM[@/*YCB2N?Q=3K%*JKGA\>VR;< WAY
MV(>K)F!QBK) =DHFL4Q46+D_:&Y.*Y2P;% 86+5'LYQR*=4O/BB9R*IJ8@SL
MJDJD<JB2J2F:*(=-5)0@B11-0A@,4P"(" \0U!>@O3VNM+2-$1HB-$1HB^>;
ML+JG5"Z=^>+SFS&73^RWD"7M=+G\>+QEUQED)*(2B96U05D-)-5($&+LSPJ]
M=2(7F.*8IJ&\G'@(9MBLVQ5O_P#:X];3_I0N?YN\X?QKJQ*1*RBD=5SK-SUT
MI\'8NEJX@Z]-6FOQ,]-CC_-*(0\+(RK1G*2HJN906R7Q>R6.MS* ) Y.)O)Q
MTB4B5&;>KM+W.V_KQ8TS95<"96L.(8_+6W66?Y*B:9,/:6SCX*(KA)QZXGD6
MQF*3:)504*N<3<$Q(/-]C3I5Z5EO6KVK;E,O]3#:_D3%F"LHY"HE<;8D+/V^
MHT^7FZ_#&BLF1\C)!(R;)NHV:BQ8$%97F,'(F F'R:&]0WIO-$!!%(! 0$$R
M (#]D! H (#]L-5:7)HB-$74ST#"6F%E:W9(F.GJ_.L'45,PLLT0?QDI&OD3
MMWC%^R<D4;NFKE XE.0Y1*8!\NB)4K=U[/?DK'.3?Z1?2YRLZQ7;6$@O-,\6
MREIDJPX@7BJPN%&^.[ZW(X[*)4./ (N7*=N5, )VQB\"!(+)"P"O]4GKC[1T
MDZ=N?V.36;$(H"-OSV+CNTMWKQ)(>Q1$UVQ0E.460.L4G'M3M174$>8WE$0T
MM"1(O7?O>OEU)+>E\1XPZ8-A1M3SBDR._J^:[>F0ZGN$U B(RK5Q944SB \3
M. )Y/+Y-(I%:ED]@O6NZL$_#O]ZMY2V\X1;2"+Y&F3?FD,U9M3F34\XA</U)
M=4TK-)-N!47%A<I*E.'E$H\PC+2D"4S?L>V#;?-@>+R8YPC7C_&$D#=S>,B3
MH-W=XO\ +HD$H2%@DTD4BD;(B80;,FY4VC4@\"$YA,8VEJ$%,Q\Q92C)Y&R3
M-K(QT@U79/V#YNB[9/F3I(Z#IH\:N"*(.6KE!0Q%$SE,0Y!$! 0'1$JGO@]G
M?F4,@*[A.FQD$F'KVUE%K&ABJ1L,I5XV*FU%3+'<XPOL<*KZJD744']P/ ,T
M3#B!5BIB"02"R1L6E:MU)NN]LR1+3-RFSFQ9^BH4@(!<I#'ECD)!5H@/(14^
M1L1A(UB347 >/;O&ZC@_'W7 0$-(E(E9N\Z^W4>MB?Q%C7I@6)*V/@,G'&?U
MO-5L2*<W A3_ !/&U2NN%^S,8!']T%+_ (_)I%(K4LEL3ZV?5@G8ASO-NQ=N
MN"1?MWXTV8\U@6C-H4XF!6)P]6%U'DO-$0\B2MA<I"4Y2F,(#Y=+4M3-&QK8
M#M\V 8Q-CS"4"N>2ESH/+SD*?,B\NM[ED4P(5Y,R"::9&[%OY0;,6Y4VK8H^
MY*)Q,<UA!4""6]Z.6TW<YB;JPYNR?DW F5:%CJ9@<[HQ-WM5-F(:LR*TU>8A
MY$)LY9XW3:KGDFB1E$0*8>T(41#R!K(4"\[/=INYRI]>W(N;K-@3*L#A^0RA
MN)DF.3)6FS#*E.X^?1D@A'B$^LW*P4;RHJ%! P&X*<0X:HO07IQS56D:(J7.
MLETM87J X=+;: TCXG<YBJ,>N<=S2O*V1N<. ^=R&.;"Y('$6\@8@GCES\P-
M'HAQX)J'$L*A$52?[/3L]W4X#WS76W9LV]Y9Q95EMO=XKB%BN]-EX*$<3SB\
M8[<MXIM)O$"-'#QPWCEU$RD,/:)I&,7B <= H%(G./5^ZX5#S7F&C8XZ2KJ\
MX\I>4;]4Z%=BXXSD[+<:97K5*Q-8M(.XV7)'.@L$*T0=]HW*5 _:\2 !1#4B
M5[ ERR(EUJU=_;4]?7_HV._YL,__ ,<Z1*OARO6_M^I']M3U]?\ HV._YL,_
M_P <Z1*>'*];^WZE:#TK=_O4KW:Y@R-3-ZNP];:G0ZSC]G8JG<%:ADRNA9+2
MM/)1Z]>!S=G[I@N*,8<SCD1 %0X<1'EU0L/:QH[)B5>UJKQHT1&B(T1&B(T1
M&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1
M&B(T1+K;5&60,A8I&RSVWZV9G<OLCY49*9'DM\4ICAU)L([(UBC&J/YEK3**
ML2C!,6Y6J9  .U(@!R^0X:^AZH:>15>$RH;) EL[ I@^!+ <4+8FWZ5^9>3Y
M>HZGH_O53ILZN>ZJJ!X[M5=(+@V<]H'A;P+0P#=&T"/2KV9YN2OX8FVL0#F-
M)#8RE$HTOQLYEG; &%67*T#X]777=R3AKV1?W490YU3%YQ,(CQUT:6=^L:7P
M,9HC9",7;.C]"_0E2T4^A3&28M#*1P;VBXB$LP[9)+B/6B2;XJH/:EFK+^W;
M:]B"ZYLN5CR5MXS/CQ*40R]87[J4MVW[(MD(]!"%O<HKS+O<23DDJ1.,EU#F
M5AG1BH.1[ Z2A>VZI14>HZG-DT3&R]0DS(>&!!LU@Z6CHF 8F^D+1;$+XMR?
MKNM<L\I45?K\^;5<M5U-O"I>2Z91SGQ@V:Z\T[W62YA,93NR[LD$34Z7MFL%
MQV%;;K/:IZ5M$_,4QZZDI^;D7$M*2BPV>>3(Y=R+M19P[.*)"@!C&'W(!P\G
M#7#<SRY<G7JF5*:&RP^P 0 [(Z%WKY2U=37?+O2ZNLF/G5+Y!+GN<7.<=]]I
M<8DV*.6T;.6ZT*KEYI6=OS_.D#&;E\[1<5=YO/M7JSE-DQN2Z2%?;PEDB9&2
M9L((/VA$.T[+D#W  'DUR.K4.E&;*,RH$B8::42T2G.M+;X@@1-ZZQR7K_.'
MN=:RETUVH4[-5JVMFOK)<LP$TP8&O:7 ,N%L-BD9TT;9;KMM/K]BO3N6=6=U
MD?-S>0)-39[$^C@89>N;%M##,F$2OF\,U;D;(F( )]DD4"@!0 -<=S)*DR=5
M=+D >$)<N$! &,MIC#HC>NS_ "KK*VOY.EU.H.>ZK-55 [SM\MA4S0&[W2&@
M0'1 6*#6]_-MUS;G&R8CQ;);G*W3]NM<DGOY_P"WC&-]O,;:-T+YFRD*E2[+
M,4QDY;#5:#&F(K,L%SB5RK(%3,7]J'7.Z)0R:*A;5U0I73JEP[,U[&EL@1#G
M-#CB<<)Z(1Z5T#GW7J_7M?FZ-I#M6E4.F2G'QJ.1-FMF5Y ,N4]TH$>'); S
M6'$7PA8K/-GFXE'<Y@FJY%>1+RK7AJ+FIY4HTLU6C9RBY,K1PC[97)B)=IH/
MHQ=)\3MT4UDTSBV73-P\NNL:QIQTRN?3@AT@]ICA:',=:T@BPV6?I"^K\D\S
M-YKY>DZF]CI->(RZB4X%KY4]EDQCFF!:8V@$ [I"K[KUAW)5C=7OCS+C2=MF
M5JGB_+]#JUUVVO9-5ZWF\>.,-T><<2^'$':H-8#)%=D'CAV1IQ(UFD5%$#\J
MPHG#L$V5ILS2J&CJ6LE39LESFSH0@_Q'"$S:PB C>VPW17S>FJN:*3F_7]<T
MJ9.K*.DK94N;0ET0^2::4XNI@3!D]CBYV[8V:"6F#MTK;73^S>TSMGG?G:JS
M>9.YXZ_^R,2*41%V_>K,JZT>XR24F89I$O3\U>?-IA)5-^SY$E$GB1RJ%Y@'
M7J:_1&AH*"5,8&5'AS-Z $3!]AB+Q"X[%S/RWU]G,/,/,592U#Y^F>]4_@Q)
M(8#([30TX"' A[8 AP((B%V&0@;YTWP7';WFJ[VFIXII>'*)=L7XV@;=.XW9
MYEGK/*SK&ZV:5L5>?PLW;4J,LR9LDHIN]!!N=R*RJ1A. ZQ3QH=$9J%$QCZI
M\YS7O+0_PPT M: 00W>B3O$1,( KRZEN<P<_3^6M>J)TG1Y%#)FR)#)CY J7
MS'/$U[GL<U\SPB&M$L.@"[>(,5OC"U+Q9B7,EHQOC7-UJF"C2&DU)X G;I(Y
M(944Z4L5FG<64S87<W:*F:7 _FQHUP_\V<<G:HHE$IC:]&MG5571MJ:F0UO;
M@)H:&;UD=V @UT+X@1%Q*[#H5#I&C:W-TO2Z^<\>[ASJ-\UT\2NU#Q YY?,E
M[V'<<_=.)K1 K"\F6>R,^HOM9J;2>EVU7F=ONXZ5EZZ@_<I0LI)Q4SC!.,D'
M\<10&KIY')NU2HJ'*)DP5-RB',.O-32I1Y=JIQ:#-;420#"T A\0#U]*]'5:
MNJ9\S=(HV3'BD?IM:YS 3NN<UTC=);<2V)@3=$PO6(]1AI=9XVT&DT;)UTQ+
M*7K=76J^I;:-)'82;8 H&09-B1XW$?-)J))*L$%7#%P4Z#@B?*8/L"'EY==)
ME^]SI\IDUK*5QW7"(Q,!AL,"8$6A>C\SF5]0=%H-/JY]'-J-88SQ)3H.'^C.
M<(BYS=X ECK'0@5%7/VZ+*B5WVEX&R>_>XTW#5O==CJ.NS:JOG\33\XXU=,9
MQNWR+15"G2&5I\XLDG\9Q2HF6B'XB@L42 FH;EM/TNE,BKKZ8"9I[J1Y;O0+
MI;XCL.V.'0ZYPM"ZCS'S;JXK]&Y>U9SJ7F65K$D31+);+JI!#P)TKUI3S#?E
MFV6_LN$($STW^9(N.,\&1<A5;7(8XCK1EC%U!R'E>*:D<2.*,9W&T-8BXWUF
MLNW=-(ES%L5@23?KIF28G< N/ 2 8.!T"FDU-<6S6"8YLI[V2R;'O:V+6G;'
M8+X07T/YC:I7:5R^R91SG4LJ=62),ZH:(NIY$V8&S9P)!#2T6!Y$&;V]T14$
M]T;6B;/8$F8Z)7\Z?FO MJO8#;AZQO"BI.5N<D[DDF+V 7QQE*UV*.R0:235
M)YP@E&F*N1P)F_9&(!B\YI9J-7F>YSW2/%<7#PG4Y :(1!WV-!9#H,;(6Q7S
M[FUFG<DT_P"=Z?*U#W26V6_WQFI-<Z:XN@6&343'B?O=(#+8]F$(J[* DR3<
M%"S*93D)+Q,=)D(H!2J$(_9HNBE4*0QB <H*\! !$./V!UTN8W<F.9L)'ZE]
MXIIHJ*>7/%SV-=^L KT+FLJWI]K<(*J(+H5J=6172,)%454HMT=-5,Y1 Q5$
MSE 0$/* AJR0#.8#=O#_ !7CKG%M%.<TP<)3R#L[)5+&%-P>\)?ISP\NAMTE
M;.W';C<7Q,T/MQE3;6-T"=;L*GYZJ13R'7GR2+$2><$2%<7 F2 "F >&NYUN
MGZ..82TU(:?>&CPQ)="\=F(,(=%T%\*T+F3G9WRR9.&F/FM_*YI]Z-;+#SV'
M_P"KNEI?O"\",;+U9YL\E9.=VJ;=YF:DGLQ+RF',?OY*5D7*SQ_(OG5;CUG+
MQX[<&.NY<N%3B8YSB)C&'B.NLZNUK-5J&, #!.> !8 (FP+ZOR3.G5'*&F3Z
MASGSWT,DN<XQ+B6"))-I)-Y5/&WQGD*^P62I^8V_VK-2IMP6?(MM?'V]V3Q>
MJO%Q&4[+&Q\4C2UI=N,4TA&;<J")2AR&3('+Y/('<-1-/(F2V,J&2?\ ;RCN
M"F#[2P$G>A;&\KXERW+U+4:>JJ9^FSJ\_F58T33JKI$6MJ)C6M$K>&Z&@0'1
M *]J'<5['V-63^14+6ZQ4:@63DU).>7GDX&)B8L7TD9[9'KARO*IQB"*G.Z.
MH<52DY^/EUT5XF5%26M[4U[X" A$DP$ +H[%^A)#J;3=*;,FGPJ23)WG;SR_
M<:UL71>22[= ,71,812\Q=XV7"9*+OO-6]WA*:OD9*+5Q,KAO(B6#T=DJC0L
M6CD!2:48#6$[VBX,-O/(@J"8MC>;";E+RZ^A?D]'[M^1;U)XWAQ\3Q&>+[S?
MNPCO;OV<-MJ_-@YWUD:I_P#0O"UKW$U.[[O[M.%+^5PW1.WH>'XH/^YWXW=B
M,+$P[*V*-GL;2=LJTNWDHB7I+Z?K\Y%."JM7K!]!*R$7*1[I(>!T5T%"*I'*
M/E 0$-?/62W2ZD2IH@\/ (/008$%?I2=4RJC2WUE(\/DOIR]CVFP@LBUP(Z"
M($%10Z=5\5LVR7;1,6RX_'UJEL;12\M)3LZF_G9&04=O2&4?N';E1XY=GX
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MC4U?C?MLMF;CP#^[U>[!7DCR%O \1/X3)SG_ +_WOM-Y=1LR\.K]X'^/&8_
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MK\/[77U"EX65YKE,_1A&'N^KU+\F:KYO6?"'&3K\68[,]I]YWXJ_&V_5XNO
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;_%UJZ+\3:OP.*GRL_*/$]?W7<4I=<4NW+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tlogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 3 $- P$1  (1 0,1 ?_$ ,P   $$ @,! 0
M      H !@@)! <#!0L! @$  P " P$               $"!@<#! 4($
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MNM'1OK(H^U.GNY["C:&E;#T76;Z*<TE!3BBM12U;7"B'[T'DD@JX(59A!MB
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M#V*5I8$(7KYI;\UO3Q]MLC^*;C"*F29%N/U868^RFK?Z3G6#DCZ4^OE:1_\
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MJ6U+P[G)=)5LX(HXC$S&,!0WC<A2E(7,'@D/!&%8:I /_,Y?WAMOO^5^W/\
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M =Y-'<5*\VF[/23I%K*;L[@L==*Q$^\WC.20$V[:K551YC ([68HO6^9_=4
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M-O*Z!9:K+EU.LY"2:UY<5G)E,^;0:;PI7+=JZ*560-L',7A\@.P.: .:,^
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M(/\ $?\ ULH7\";B?DKA.%65/P2_2#_$?_6RA?P)N)^2N!PC*GX)?I!_B/\
MZV4+^!-Q/R5P.$94_!6(:6]6^G_6A;52[NFZOFUQ[?)5!*TLI/M(V7BDBSL*
M*(23$6LVPCGFTV%<N9MWL#GZ".&HE$Q+'BI(X$D/#)?+2:"921D))Q55]@7D
MGSR07*2KX $P7>N5'2H$*-*B($!14<@$1R#"9)EA?HRN@/\ E5?C\+Z?_)3
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M<OQA61YX^T'H(HOD!P,AE?;8C3=8K3)2"5"6%M=2-L:8)L&794S&)MG$DLF
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MD!RP<LY/ #X_!<BRR3=)5==5-!!%,ZJRRQRII)))E$ZBBJAQ*1-,A $1,(@
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M2#8,85MQ$I8HJ>;-]22YR&_\J?F*8H_]T5$IBB'_ %#C5EO]2(^(_BOKN_\
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M442E*.>T %#USQB^DD;FNMRGC(W8D_%Y!UN#=[<-/L&ILV!3;AH[@B!R MD
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9G]LRY9>=3F-F3>JGRN[\.3*8>/'6;+__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
